Cargando…
Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment
For coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 15–30% of patients are likely to develop COVID-19-related acute respiratory distress syndrome (ARDS). There are still few effective and well-understood therapies available. Novel variants...
Autores principales: | Que, Haiying, Hong, Weiqi, Lan, Tianxia, Zeng, Hao, Chen, Li, Wan, Dandan, Bi, Zhenfei, Ren, Wenyan, Luo, Min, Yang, Jingyun, He, Cai, Zhong, Ailing, Wei, Xiawei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789731/ https://www.ncbi.nlm.nih.gov/pubmed/36566328 http://dx.doi.org/10.1038/s41392-022-01283-6 |
Ejemplares similares
-
Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice
por: Bi, Zhenfei, et al.
Publicado: (2021) -
Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy
por: Lan, Tianxia, et al.
Publicado: (2022) -
TFAM deficiency in dendritic cells leads to mitochondrial dysfunction and enhanced antitumor immunity through cGAS-STING pathway
por: Lu, Tianqi, et al.
Publicado: (2023) -
A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome
por: Hong, Weiqi, et al.
Publicado: (2021) -
Antitumor and Radiosensitization Effects of a CXCR2 Inhibitor in Nasopharyngeal Carcinoma
por: Liu, Xiaobei, et al.
Publicado: (2021)